Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,201 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Melanoma Neoplasms Clear all
Completed Early Phase 1 Interventional

Burosumab for CSHS

NCT03993821
View directory record Official record
Conditions
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions
Burosumab
Drug
Lead sponsor
Laura Tosi
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

NCT02346955
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions
CM-24 (MK-6018), Pembrolizumab (MK-3475)
Biological
Lead sponsor
Famewave Ltd.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

NCT03089606
View directory record Official record
Conditions
Melanoma
Interventions
FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab, CT scan
Diagnostic Test · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)

NCT01711684
View directory record Official record
Conditions
Neoplasm Metastasis, Melanoma
Interventions
Diphenylcyclopropenone (DPCP)
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

NCT00002952
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, recombinant MAGE-3.1 antigen, recombinant interleukin-12
Biological
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational

Role of Metabolic Enzymes in Non-Melanoma Skin Cancer

NCT02244749
View directory record Official record
Conditions
Skin Cancer
Interventions
skin specimen
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312
View directory record Official record
Conditions
Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Orange, California • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804
View directory record Official record
Conditions
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Interventions
OR2805, Cemiplimab, Docetaxel
Drug
Lead sponsor
OncoResponse, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Phase 2 Interventional

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

NCT06265285
View directory record Official record
Conditions
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration
Other · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 2 Interventional

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

NCT00060125
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
tipifarnib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 30, 2026, 9:09 AM EDT
Not listed Phase 1Phase 2 Interventional

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

NCT02913417
View directory record Official record
Conditions
Uveal Melanoma, Hepatic Metastases
Interventions
SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
Device · Drug
Lead sponsor
David Minor, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study of Infrared Imaging of Cutaneous Melanoma

NCT00937690
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Early Phase 1 Interventional

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

NCT04581382
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Pembrolizumab, Radiation Therapy, Therapeutic Exchange Plasma, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 30, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

NCT01689974
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Sep 30, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

NCT06034860
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Interventions
MT-8421, Nivolumab
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Sep 30, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

NCT01341496
View directory record Official record
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
Interventions
Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

NCT00003362
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
QS21, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

NCT06153238
View directory record Official record
Conditions
Melanoma
Interventions
GME751, Keytruda - EU, Keytruda - US
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Orange, California • Clermont, Florida • Orange City, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Phase 2 Interventional

Palbociclib and Pembrolizumab In Central Nervous System Metastases

NCT02896335
View directory record Official record
Conditions
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
Interventions
Palbociclib, Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

NCT03159117
View directory record Official record
Conditions
Melanoma
Interventions
PF-06688992
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

NCT01740297
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, Ipilimumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Not applicable Interventional

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

NCT00049010
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
27
States / cities
Chicago, Illinois • Cedar Rapids, Iowa • Boston, Massachusetts + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Sep 30, 2026, 9:09 AM EDT